Almirall, S.A. (LBTSF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Almirall, S.A. (LBTSF) trades at $15.35 with AI Score 54/100 (Grade B). Almirall, S. A. is a biopharmaceutical company focused on skin health. Market cap: $3.30B, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for LBTSF: LBTSF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates LBTSF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
LBTSF: 2/4 perspectives are bullish. Dominant signal: Seth Klarman bullish.
Almirall, S.A. (LBTSF) Healthcare & Pipeline Overview
Almirall, S.A. is a global biopharmaceutical company specializing in dermatology, offering a diverse portfolio of branded and generic medications for skin conditions. With a focus on research and development, Almirall serves patients and healthcare professionals across Europe, the U.S., and other international markets, maintaining a presence in a competitive pharmaceutical landscape.
What Is the Investment Thesis for LBTSF?
Almirall, S.A. presents a focused investment opportunity within the specialty dermatology sector. The company's established presence in Europe and growing footprint in the U.S. provide a solid foundation for revenue generation. With a market capitalization of $3.29 billion and a dividend yield of 1.39%, Almirall offers a blend of growth and income potential. Key value drivers include the continued commercial success of its flagship products like Ilumetri and Klisyri, as well as the successful development and launch of new pipeline assets. The company's commitment to research and development, evidenced by its collaborations with various biotech firms and academic institutions, supports long-term growth. However, investors should be aware of the risks associated with the pharmaceutical industry, including regulatory hurdles, patent expirations, and competition from generic alternatives. Almirall's P/E ratio of 41.53 suggests a premium valuation, reflecting investor expectations for future growth.
Based on FMP financials and quantitative analysis
LBTSF Key Highlights
- Market Cap of $3.29 billion indicates a significant presence in the biopharmaceutical industry.
- P/E ratio of 41.53 reflects investor expectations for future earnings growth.
- Gross Margin of 55.2% demonstrates strong operational efficiency and pricing power.
- Dividend Yield of 1.39% provides a steady income stream for investors.
- Beta of 0.15 suggests lower volatility compared to the overall market.
Who Are LBTSF's Competitors?
LBTSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARSUF Fagron N.V. | $26.53 | +0.00% | $1.95B | 54 |
| CASBF CanSino Biologics Inc. | $3.10 | +0.00% | $1.08B | — |
| CHSYF China Medical System Holdings Limited | $1.35 | +0.00% | $3.27B | 53 |
| CURLF Curaleaf Holdings, Inc. | $10.43 | +0.38% | $2.76B | 53 |
| DMPHF Dermapharm Holding SE | $39.56 | +0.00% | $1.96B | 50 |
| ALVO Alvotech | $4.44 | +5.21% | $1.39B | 69 |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are LBTSF's Key Strengths?
- Strong presence in the European dermatology market.
- Diverse portfolio of branded and generic medications.
- Commitment to research and development.
- Strategic collaborations with other companies.
What Are LBTSF's Weaknesses?
- Reliance on a limited number of key products.
- Exposure to generic competition.
- Relatively small presence in the U.S. market.
- High P/E ratio compared to some competitors.
What Could Drive LBTSF Stock Higher?
- Continued commercial success of key products like Ilumetri and Klisyri.
- Expansion into new geographic markets.
- Positive results from ongoing clinical trials.
- Potential regulatory approvals for new products.
- Strategic collaborations with other companies.
What Are the Key Risks for LBTSF?
- Patent expirations on key products.
- Increasing competition from generic drug manufacturers.
- Regulatory changes and pricing pressures.
- Unsuccessful clinical trials or product recalls.
- Limited liquidity due to OTC market trading.
What Are the Growth Opportunities for LBTSF?
- Expansion into New Therapeutic Areas: Almirall has the opportunity to expand its product portfolio beyond its current focus on dermatology to include other therapeutic areas with high unmet needs. This could involve developing or acquiring treatments for conditions such as autoimmune diseases or oncology-related skin disorders. The market for these therapies is substantial, offering significant revenue potential. Success in this area would require Almirall to leverage its research and development capabilities and establish strategic partnerships with companies specializing in these therapeutic areas. Timeline: 3-5 years.
- Geographic Expansion: Almirall can further expand its geographic footprint by entering new markets in Asia, Latin America, and other regions with growing healthcare spending and increasing demand for dermatological treatments. This would involve establishing local partnerships, navigating regulatory requirements, and tailoring its product offerings to meet the specific needs of each market. The potential revenue upside is significant, but Almirall would need to carefully manage the risks associated with international expansion. Timeline: Ongoing.
- Strategic Acquisitions: Almirall can pursue strategic acquisitions of smaller biotechnology companies or pharmaceutical assets to enhance its product pipeline and expand its technological capabilities. This could involve acquiring companies with promising drug candidates in dermatology or related therapeutic areas, or acquiring technologies that complement Almirall's existing research and development efforts. The success of this strategy depends on Almirall's ability to identify and integrate suitable acquisition targets. Timeline: Opportunistic.
- Development of Novel Formulations: Almirall can invest in the development of novel drug formulations and delivery systems to improve the efficacy and patient compliance of its existing products. This could involve developing topical formulations with enhanced penetration, sustained-release formulations that reduce dosing frequency, or innovative delivery systems that target specific skin layers. The market for these advanced formulations is growing, driven by the demand for more convenient and effective treatments. Timeline: 2-4 years.
- Leveraging Digital Health Technologies: Almirall can leverage digital health technologies, such as mobile apps and wearable devices, to improve patient engagement, monitor treatment adherence, and collect real-world data on the effectiveness of its products. This could involve developing apps that provide patients with personalized skincare advice, track their symptoms, and connect them with healthcare professionals. The use of digital health technologies can enhance the value proposition of Almirall's products and create new revenue streams. Timeline: 1-3 years.
What Opportunities Does LBTSF Have?
- Expansion into new therapeutic areas.
- Geographic expansion into emerging markets.
- Strategic acquisitions of complementary businesses.
- Development of novel drug formulations and delivery systems.
What Threats Does LBTSF Face?
- Patent expirations on key products.
- Increasing competition from generic drug manufacturers.
- Regulatory changes and pricing pressures.
- Unsuccessful clinical trials or product recalls.
What Are LBTSF's Competitive Advantages?
- Patent protection for key products provides exclusivity and pricing power.
- Established brand reputation in the dermatology market.
- Specialized expertise in the research and development of dermatological therapies.
- Strategic partnerships with other companies enhance its pipeline and capabilities.
What Does LBTSF Do?
Founded in 1943 and headquartered in Barcelona, Spain, Almirall, S.A. has evolved from a local laboratory into a global biopharmaceutical company dedicated to skin health. Originally known as Laboratorios Almirall, S.A., the company changed its name in 2009 to reflect its expanded focus and international presence. Almirall engages in the research, development, manufacture, and commercialization of innovative medicines addressing various dermatological diseases. Its product portfolio includes treatments for actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, and acne, as well as solutions for cardiovascular, musculo-skeletal, respiratory, and nervous system disorders. Key products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, and Klisyri. Almirall has established strategic collaborations with companies like Tyris Therapeutics, BIOMAP, Kaken Pharmaceutical Co Ltd., and Eli Lilly and Company to enhance its research and development capabilities and expand its product offerings. The company operates in Europe, the United States, and other international markets, serving patients and healthcare professionals with a commitment to improving skin health outcomes.
What Products and Services Does LBTSF Offer?
- Develops and commercializes prescription medications for skin diseases.
- Offers treatments for conditions like psoriasis, acne, and actinic keratosis.
- Markets products in Europe, the United States, and internationally.
- Engages in research and development to discover new dermatological therapies.
- Collaborates with other companies and research institutions to expand its pipeline.
- Manufactures its own pharmaceutical products.
How Does LBTSF Make Money?
- Develops and patents proprietary drug formulations.
- Manufactures and distributes its products through established pharmaceutical channels.
- Generates revenue through the sale of branded and generic medications.
- Partners with other companies for research, development, and commercialization.
What Industry Does LBTSF Operate In?
Almirall operates within the competitive specialty and generic drug manufacturing industry, focusing primarily on dermatology. The global dermatology market is driven by factors such as an aging population, increasing awareness of skin diseases, and the availability of advanced treatment options. Key trends include the development of biologics and targeted therapies for chronic skin conditions. Almirall competes with other specialty pharmaceutical companies, as well as larger generic drug manufacturers. The company's success depends on its ability to innovate, develop, and commercialize differentiated products that address unmet needs in the dermatology market.
Who Are LBTSF's Key Customers?
- Patients with dermatological conditions.
- Dermatologists and other healthcare professionals.
- Hospitals and clinics.
- Pharmacies and drug distributors.
LBTSF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
LBTSF Latest News
-
Stocks That Hit 52-Week Lows On Friday
· Feb 28, 2020
-
Stocks That Hit 52-Week Lows On Monday
· Jan 27, 2020
LBTSF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for LBTSF.
Price Targets
Wall Street price target analysis for LBTSF.
LBTSF MoonshotScore
What does this score mean?
The MoonshotScore rates LBTSF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Carlos Gallardo Piqué
CEO
Carlos Gallardo Piqué is the CEO of Almirall, S.A. He is responsible for managing the company's overall strategy and operations. His background includes extensive experience in the pharmaceutical industry, with a focus on dermatology. He has held various leadership positions within Almirall, contributing to the company's growth and expansion. He oversees a workforce of 2026 employees and is instrumental in driving Almirall's innovation and market presence.
Track Record: Under Carlos Gallardo Piqué's leadership, Almirall has focused on expanding its dermatology portfolio and strengthening its presence in key markets. Key achievements include the successful launch of new products and the establishment of strategic collaborations to enhance research and development capabilities. He has also overseen the company's efforts to leverage digital health technologies to improve patient engagement and treatment outcomes.
LBTSF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Almirall, S.A. (LBTSF) may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB, or a major exchange like NYSE or NASDAQ. Companies in this tier are often smaller, earlier-stage, or may have limited trading volume. Investing in OTC Other stocks carries higher risks due to the potential for less transparency and regulatory oversight compared to exchange-listed companies. Investors should exercise caution and conduct thorough due diligence before investing in LBTSF.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity compared to exchange-listed stocks.
- Less stringent regulatory requirements and disclosure standards.
- Potential for greater price volatility.
- Higher risk of fraud or manipulation.
- Limited access to company information and financial data.
- Verify the company's financial statements and SEC filings (if available).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's growth prospects and potential risks.
- Monitor trading volume and bid-ask spreads.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- Established presence in the European dermatology market.
- Diverse portfolio of branded and generic medications.
- Commitment to research and development.
- Strategic collaborations with other companies.
- Presence of a CEO with industry experience.
What Investors Ask About Almirall, S.A. (LBTSF) — Healthcare
What does Almirall, S.A. do?
Almirall, S.A. is a global biopharmaceutical company focused on developing and commercializing prescription medications for dermatological diseases. The company's product portfolio includes treatments for conditions such as psoriasis, acne, actinic keratosis, and other skin disorders. Almirall operates in Europe, the United States, and other international markets, serving patients and healthcare professionals with a commitment to improving skin health outcomes. The company also engages in research and development to discover new therapies and expand its product offerings.
What are the main risks for LBTSF?
Almirall, S.A. faces several risks common to the pharmaceutical industry, including patent expirations on key products, increasing competition from generic drug manufacturers, and regulatory changes and pricing pressures. The company's reliance on a limited number of key products also poses a risk, as a decline in sales of these products could significantly impact its financial performance. Additionally, Almirall faces risks associated with clinical trials, product recalls, and intellectual property disputes. As an OTC-traded stock, LBTSF also carries liquidity risks.
What are the key factors to evaluate for LBTSF?
Almirall, S.A. (LBTSF) holds an AI score of 54/100 (moderate). Not financial advice.
How frequently does LBTSF data refresh on this page?
LBTSF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven LBTSF's recent stock price performance?
Almirall, S.A. (LBTSF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong presence in the European dermatology market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LBTSF overvalued or undervalued right now?
Valuing Almirall, S.A. (LBTSF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying LBTSF?
Before investing in Almirall, S.A. (LBTSF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding LBTSF to a portfolio?
Key strength of Almirall, S.A. (LBTSF): Strong presence in the European dermatology market. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data and market information are based on available sources and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.